Scientific article
OA Policy
English

Dexamethasone for the treatment of established postoperative nausea and vomiting: A randomised dose finding trial

Published inEuropean journal of anaesthesiology, vol. 39, no. 6, p. 549-557
Publication date2022
First online date2021-11-16
Abstract

Background: Dexamethasone is widely used for the prevention of postoperative nausea and vomiting (PONV) but little is known about its efficacy for the treatment of established PONV.

Objective: To test the antiemetic efficacy of intravenous dexamethasone for the treatment of established PONV in adults undergoing surgery under general anaesthesia and to determine whether there is dose-responsiveness.

Design: The DexPonv trial is a multicentre, placebo-controlled, randomised, double-blind, dose-finding study. Inclusion of patients was between September 2012 and November 2017. Follow-up for PONV symptoms was for 24 h. Thirty days postoperatively, patients were contacted by study nurses for any information on postoperative bleeding and infection.

Setting: Four public hospitals in Switzerland.

Patients: A total of 803 adults scheduled for elective surgery without any antiemetic prophylaxis signed the consent form; 714 were included. Among those, 319 had PONV and 281 patients were eventually randomised (intention to treat population and safety set). The per protocol set consisted of 260 patients.

Interventions: Patients with PONV symptoms (including retching) were randomised to a single intravenous dose of dexamethasone 3, 6 or 12 mg or matching placebo.

Main outcome measures: The primary endpoint was the absence of further nausea or vomiting (including retching), within 24 h after administration of the study drug.

Results: Dexamethasone was ineffective during the first 24 h, whatever the dosage, compared to placebo, even when the model was adjusted for known risk factors (P = 0.170). There were no differences in the time to treatment failure or the quality of sleep during the first night. There was a positive correlation between the dose of dexamethasone and blood glucose concentrations (P < 0.001), but not with bleeding risk, wound infections or other adverse effects.

Conclusion: This randomised trial failed to show anti-emetic efficacy of any of the tested intravenous regimens of dexamethasone for the treatment of established PONV in adults undergoing surgery under general anaesthesia.

Trial registration: clinicaltrials.gov (NCT01975727).

Keywords
  • Adult
  • Anesthesia, General / adverse effects
  • Antiemetics
  • Dexamethasone
  • Double-Blind Method
  • Humans
  • Postoperative Nausea and Vomiting / diagnosis
  • Postoperative Nausea and Vomiting / drug therapy
  • Postoperative Nausea and Vomiting / epidemiology
Funding
Citation (ISO format)
CZARNETZKI, Christoph et al. Dexamethasone for the treatment of established postoperative nausea and vomiting: A randomised dose finding trial. In: European journal of anaesthesiology, 2022, vol. 39, n° 6, p. 549–557. doi: 10.1097/EJA.0000000000001636
Main files (1)
Article (Published version)
Secondary files (2)
Supplemental data - Supplemental table 1
accessLevelPublic
Supplemental data - Supplemental table 2
accessLevelPublic
Identifiers
Journal ISSN0265-0215
374views
402downloads

Technical informations

Creation16/02/2022 14:58:00
First validation16/02/2022 14:58:00
Update16/03/2023 06:47:45
Status update16/03/2023 06:47:43
Last indexation01/11/2024 01:58:25
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack